Legend Biotech’s Earnings Spark Fresh Interest in the Stock

Legend Biotech (LEGN) recently released first quarter 2026 results, reporting revenue of US$305.1 million and a net loss of US$54.3 million. This compares with revenue of US$195 million and a net loss of US$101 million a year earlier.

Legend Biotech’s 1 day share price return of 10.48% came alongside the earnings release, while the 30 day share price return of 55.62% suggests momentum has picked up recently, even though the 1 year total shareholder return declined 9.07%.

If this kind of rebound in biotech catches your eye, it could be worth scanning other healthcare names using our screener of 33 healthcare AI stocks.

With revenue at US$305.1 million, losses narrowing and the stock up more than 50% over 30 days, the key question now is whether Legend Biotech is still trading at a discount or if the market is already pricing in a higher valuation.

Most Popular Narrative: 50.6% Undervalued

The most followed narrative pegs Legend Biotech's fair value at $57.24, which is roughly double the last close of $28.26, and frames the upside around multiple myeloma execution.

Significant expansion potential in both earlier lines of therapy and frontline settings for multiple myeloma, driven by strong survival data, ongoing clinical trials (CARTITUDE-5 and -6), and label updates that increase patient access, setting up long-term revenue acceleration as the patient pool widens.

Curious what kind of revenue path and margin shift sit behind that valuation gap? The narrative leans on rapid top line growth, a sharp swing to profitability, and a richer future earnings multiple than the broader biotech sector.

Result: Fair Value of $57.24 (UNDERVALUED)

However, you still need to keep in mind that Legend Biotech depends heavily on CARVYKTI and faces rising competition that could pressure future revenue and margins.

Next Steps

Does this narrative feel optimistic or cautious to you? If you want to move quickly from headline takeaways to your own view, start by checking the 2 key rewards.

Looking for more investment ideas?

If Legend Biotech has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to spot other opportunities before they move without you.

• Target potential mispricings by searching for stocks that combine quality and value through the 45 high quality undervalued stocks.
• Prioritize resilience by focusing on companies screened for strong finances using the solid balance sheet and fundamentals stocks screener (46 results).
• Get ahead of the crowd by reviewing the screener containing 22 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.